80 results about "Diabetic kidney" patented technology

The invention relates to a flavonoid active fraction of an Abelmoschi corolla, a preparation method and an application thereof, and belongs to the field of traditional Chinese pharmaceutics. A high-purity Abelmoschi corolla flavonoid active fraction is prepared, which is found to have better therapeutic activity for kidney disease, and especially have a significant therapeutic effect for diabetic kidney disease and lupus nephritis, or contrast-induced kidney injury and eye diseases. Meanwhile, the Abelmoschi corolla flavonoid active fraction described in the invention also has good safety.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and / or non-diabetic kidney disease (NDKD).

The invention provides application of AQP1 protein as a target spot in preparation of a diagnostic reagent and a therapeutic drug for hypoglycaemia nephropathy, and belongs to the technical field of biological medicines.The AQP1 protein is used as the target spot, AQP1 protein expression is reduced by adopting an inhibitor, and the hypoglycaemia nephropathy is obtained. According to the present invention, with the application of the kit, the effects of reducing the renal tubule injury markers in the urine, reducing the glomerular filtration rate or relieving the kidney tissue hypoxia can be achieved, the new idea is provided for the early prevention and treatment of the diabetic nephropathy (DKD), and the early recognition and the effective treatment of the kidney injury of the diabetic patient can be well achieved.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating diabetic kidney diseases and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10 to 60 parts of raw radix astragali seu hedysari, 5 to 30 parts of rhizoma polygonati, 5 to 30 parts of rhizoma dioscoreae, 5 to 30 parts of fructus corni, 3 to 15 parts of rhizoma coptidis, 5 to 30 parts of ramuli euonymi, 5 to 30 parts of fructus arctii and 3 to 15 parts of leech. The traditional Chinese medicine composition preferably selects the raw material medicines and compatibility thereof, focuses on strengthening spleen and middle warmer, tonifying spleen and kidney, strengthening spleen and reinforcing kidney, clearing heat and removing toxicity, gives full play to the treatment characteristics of multi-component, multi-path and multi-target synergistic effect of traditional Chinese medicines, and can obviously improve clinical healing of patients with diabetic kidney diseases. The early-stage small-scale clinical observation shows that the prescription for invigorating spleen, tonifying kidney, clearing heat and harmonizing collaterals can effectively improve clinical symptoms and traditional Chinese medicine syndromes of patients with diabetic kidney diseases, reduces UACR values, and has good popularization and application values.

The application provides a traditional Chinese medicine compound medicine composed of Coptis chinensis, Astragalus membranaceus, Panax notoginseng and Rehmannia glutinosa and application thereof in preventing and treating diabetes and diabetes complications, and experimental results show that the compound medicine has good prevention and treatment effects on diabetes and various diabetes complications such as diabetic heart disease, diabetic kidney disease and diabetic retinopathy.

The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and / or non-diabetic kidney disease (NDKD).

The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1, 5-a]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

The invention discloses an AI intervention analysis method for diabetic renal interstitial fibrosis, and relates to the technical field of biologication.The method comprises the following specific steps of sample collection and multi-omics data acquisition, specifically, kidney tissue samples of diabetic renal interstitial fibrosis patients before and after the diabetic renal interstitial fibrosis patients use glucose kidney health intervention and kidney tissue samples of healthy contrasts are collected; respectively acquiring epigenetic data and single-cell gene expression data, preprocessing, and integrating to construct a comprehensive data set; by combining the AI technology and the high-throughput epigenetic detection technology, the epigenetic modification change on a TGF-beta1 / Smads signal path in the process of intervening diabetic renal interstitial fibrosis by the Sushenkang can be deeply analyzed; a brand-new perspective is provided for understanding the occurrence mechanism of the diabetic renal interstitial fibrosis disease and the drug action mechanism of the TGF-beta1 / Smads pathway, epigenetic data is deeply mined through AI, and the specific mechanism of the TGF-beta1 / Smads pathway related gene expression affected by the TGF-beta1 / Smads pathway through epigenetic regulation is shown.

The invention discloses an application of a small molecule compound CB-839 in preparation of a medicine for treating diabetic kidney diseases. The treatment of the diabetic kidney disease means that the renal function and the kidney injury of the diabetic kidney disease are obviously improved by the CB-839 (C26H24F3N7O3S). The CB-839 is a glutaminase 1 (GLS1) inhibitor, and can prevent in-vivo glutamine decomposition by inhibiting the activity of glutamine decomposition enzyme so as to maintain the in-vivo concentration of the CB-839. In addition, the CB-839 shows antitumor activity in animal experiments. Experimental results show that the CB-839 can inhibit glutamine decomposition, so that the purpose of improving prognosis of the diabetic kidney disease is achieved.

The invention discloses a pentapeptide YP5 with a function of relieving diabetic kidney injury as well as a preparation method and application of the pentapeptide YP5, and belongs to the technical field of biology. The pentapeptide YP5 is screened from pacific salmon protamine enzymatic hydrolysate, the amino acid sequence is YVAAP, and the pentapeptide YP5 has the function of relieving the diabetic kidney injury, can remarkably reduce the content of fasting blood-glucose, serum creatinine, urea nitrogen and urine protein of diabetic mice, has better activity and smaller toxic and side effects than a positive drug metformin, and can be used for preparing the medicine for treating diabetic kidney injury. The method can be applied to functional food for relieving diabetic kidney injury.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The present disclosure provides at least one entity selected from a compound of Formula I, a tautomer thereof, a deuterated derivative of the compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the entity, and methods of use thereof, including use in the treatment of APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and / or non-diabetic kidney disease (NDKD).

The present invention relates to 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

The invention relates to application of uridine in the development process of a medicine for preventing and treating diabetic nephropathy and in the medicine. Clinical metabonomics identification and animal experiment verification prove that uridine is a key active metabolite of DKD, the treatment effect of uridine has the characteristics of multiple targets and tissue specificity, and a new solution for research and development of metabolic drugs based on DKD is provided; through pharmacodynamic research of uridine and exploration of a protection mechanism, various application scenes of uridine in the research and development process of medicines for preventing and / or reducing diabetic nephropathy patients are further explored, so that the application of uridine in DKD medicines and the research and development process of the medicines is wider, and a wider prospect is provided for later research and development of the DKD medicines.

Disclosed are a compound traditional Chinese medicine composition for treating diabetic nephropathy, a method for preparing same, and use thereof. The compound traditional Chinese medicine composition is prepared from Astragali Radix, Atractylodis Macrocephalae Rhizoma, Corni Fructus, Cinnamomi Cortex, Psoraleae Fructus, Rehmanniae Radix, Eucommiae Cortex, Achyranthis Bidentatae Radix, and Schisandrae Chinensis Fructus. Marsdenia tenacissima Caulis may also be added to the substance of the compound traditional Chinese medicine composition.

This invention relates to a compound traditional Chinese medicine composition for treating diabetic nephropathy and its application. The invention provides a traditional Chinese medicine composition 1 for treating diabetic nephropathy, which is prepared from Astragalus membranaceus, Atractylodes macrocephala, Cornus officinalis, Cinnamomum cassia, Psoralea corylifolia, Rehmannia glutinosa, Eucommia ulmoides, Achyranthes bidentata, and Schisandra chinensis. The invention further provides a traditional Chinese medicine composition 2 for treating diabetic nephropathy, which is prepared from Astragalus membranaceus, Atractylodes macrocephala, Cornus officinalis, Cinnamomum cassia, Psoralea corylifolia, Rehmannia glutinosa, Eucommia ulmoides, Achyranthes bidentata, Schisandra chinensis, and Clematis chinensis.

The invention relates to the technical field of biomarkers. The invention provides application of phosphatidylcholine as a marker in preparation of a kit for detecting a diabetic kidney disease and application of a reagent for detecting phosphatidylcholine in preparation of the kit for detecting the diabetic kidney disease. Phosphatidylcholine is used as the marker to distinguish pure type 2 diabetes patients from diabetic kidney disease patients, so that a basis is provided for diagnosis of the diabetic kidney disease.

The present invention pertains to the technical field of biomedicine. Specifically disclosed is use of a substance for inhibiting the activity and / or expression of a CAPG gene or protein in the preparation of a product for treating renal fibrosis caused by kidney injury. First, research has found that CAPG is expressed at low levels in normal kidney tissues, while its expression level is increased in kidney tissues of patients with acute kidney injury, minimal change disease, IgA nephropathy, lupus nephritis, and diabetic kidney disease, indicating that the expression of CAPG may be involved in the occurrence and development of renal fibrosis caused by kidney injury. Then, by means of constructing a CAPG knockout mouse model, it has been further found that knocking out CAPG can effectively alleviate the progression of renal fibrosis; and by means of culturing renal fibroblasts in vitro, it has been found that silencing or knocking down CAPG can inhibit TGF-β-induced activation of renal fibroblasts. The present invention is of great significance for the pathogenesis and treatment of kidney injury or renal fibrosis.

Described herein are 3-phenylbenzo[b]thiophene carboxylic acid and 3-phenylbenzo[b]furan carboxylic acid derivatives and uses thereof in therapy. A crystalline form of 6-fluoro-3-(2,4,5-trifluoro-3- methoxyphenyl)-1-benzothiophene-2-carboxylic acid is also disclosed. The compounds disclosed herein can be used as a branched-chain alpha keto acid dehydrogenase kinase inhibitor or a degrader to treat conditions, for example, diabetes, kidney disease, nonalcoholic steatohepatitis, and heart failure.

The invention belongs to the field of treatment of diabetic kidney diseases (DKD), and particularly relates to application of deoxycholic acid compounds in treatment of diabetic kidney diseases, the deoxycholic acid compounds have the structure shown in the formula I, and n and R1 are defined as in the specification.

The invention discloses a marker combination, an antibody chip and a kit for detecting diabetic kidney diseases. The antibody chip comprises a solid phase carrier and a capture antibody coated on the surface of the solid phase carrier, the capture antibody can be specifically combined with a diabetic kidney disease marker combination, and the marker combination comprises CTACK, HGF and MIP-1 alpha. The antibody chip and the kit for detecting the marker combination of the diabetic kidney disease show high sensitivity and high specificity in detection of the diabetic kidney disease by detecting the screened marker combination. The detection method is small in sample demand, simple and convenient to operate and low in cost, overcomes the defects that a traditional technology is tedious in operation, single in index and prone to being interfered, and provides a powerful tool for early screening, risk assessment and medication curative effect monitoring of the diabetic kidney diseases.

The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and / or non-diabetic kidney disease (NDKD).

The invention provides methods of treating kidney conditions using compositions that contain modified forms of trimetazidine, such as CV-8972. Providing such compositions increases energy production in the kidney. Therefore, methods of the invention are useful for treating a variety of kidney conditions, such as acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic kidney, or diabetic nephropathy.

Methods are provided for delaying onset or progression of kidney damage, or treating kidney disease, in a subject who has type 1 diabetes or type 2 diabetes or glomerular disease. The methods comprise administering to a subject with type 1 or type 2 diabetes or glomerular disease an effective amount of an agent capable of inhibiting NBL1 activity, and in particular, capable of inhibiting NBL1-mediated toxicity of human podocytes. In some embodiments, the agent is an antibody capable of binding to human NBL1.

To provide a bifunctional degrading agent for interleukin-1 receptor-related kinases and its therapeutic use. [Solution] This disclosure provides a bifunctional compound as an IRAK4 degradation agent via the ubiquitin-proteasome pathway, and a method for treating diseases modulated by IRAK4. The compounds of this disclosure or their pharmaceutical compositions are useful as therapeutic agents for treating inflammatory disorders such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, necrotizing enterocolitis, gout, Lyme disease, arthritis, psoriasis, pelvic inflammatory disease, systemic lupus erythematosus (SLE), Sjögren's syndrome, inflammation associated with gastrointestinal infections including C. difficile, viral myocarditis, acute and chronic tissue injury, non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, and renal diseases including chronic kidney disease and diabetic kidney disease.

The invention discloses a tetrapeptide FP4 with a function of relieving diabetic kidney injury as well as a preparation method and application of the tetrapeptide FP4, and belongs to the technical field of biology. The tetrapeptide FP4 is obtained by screening from pacific salmon protamine enzymatic hydrolysate, has an amino acid sequence of FGVP, has the function of relieving the diabetic kidney injury, can significantly reduce the contents of fasting blood-glucose, serum creatinine, urea nitrogen and urine protein of diabetic mice, has better activity and smaller toxic and side effects than a positive drug metformin, and can be used for preparing drugs for treating diabetic kidney injury. The method can be applied to functional food for relieving diabetic kidney injury.

Provided are compounds of Formula (I):The compounds target the lanthionine synthetase C-like (LANCL) family of proteins, including LANCL2 and LANCL3. The compounds can be used to treat conditions such as inflammatory diseases, metabolic diseases, autoimmune diseases, cancers, and infectious diseases. Exemplary conditions include inflammatory conditions of the liver, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cirrhosis; inflammatory conditions of the bile duct, such as primary biliary cholangitis, primary sclerosing cholangitis; inflammatory bowel disease, such as Crohn's disease and ulcerative colitis; lupus, such as systemic lupus erythematosus, lupus nephritis, and cutaneous lupus; arthritis, such as rheumatoid arthritis; hyperglycemia, such as type 1 diabetes, type 2 diabetes, and prediabetes and associated conditions such as atherosclerosis and diabetic kidney disease; psoriasis; and multiple sclerosis.

The invention discloses application of PTGDS, APOF and CXCL9 as biomarkers, and application of the biomarkers in preparation of products for early diagnosis of diabetic nephropathy and diabetes mellitus. According to the marker, related differential proteins are analyzed through combination of DIA (non-targeted data independent acquisition) and targeted Olink proteomics sequencing, then analysis and verification are performed through machine learning and enzyme-linked immunosorbent assay, and the key effect of the expression levels of PTGDS, APOF and CXCL9 in diabetes and diabetic nephropathy is proved. The invention finds that the combined characteristics of PTGDS, APOF and CXCL9 can be used as the marker for early diagnosis of DKD and DM for the first time, has sensitivity, specificity and accuracy, and has important clinical value.